公开(公告)号：EP0741745B1

公开(公告)日：2005-11-16

申请号：EP95907092.1

申请日：1995-02-02

申请人： IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE

发明人： KARAYIANNIS, Peter ,  THOMAS, Howard Christopher

IPC分类号： C07K14/02 ,  A61K39/29 ,  G01N33/576

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2730/10122 ,  Y10S435/975 ,  Y10S530/806 ,  Y10S530/81 ,  Y10S530/826

摘要： A variant and so-called 'escape mutant' HBsAg protein or fragment thereof displaying the antigenicity of hepatitis B virus surface antigen is disclosed, in which the mutant protein or fragment thereof (mHBsAg) comprises a modified 'a' determinant in which at least two amino acids are inserted downstream of position (122) of the wild type HBsAg sequence. A vaccine comprising the mHBsAg is provided, as is a kit for diagnostic in vitro detection of anti-mHBsAg antibodies and an antibody preparation comprising anti-mHBsAg antibodies.

公开(公告)号：EP1499748A4

公开(公告)日：2005-10-12

申请号：EP03721825

申请日：2003-04-11

申请人： MERCK & CO INC

发明人： FLORES OSVALDO A ,  GROBLER JAY ,  MURRAY EDWARD M ,  ZUCK PAUL D

IPC分类号： C07K14/02 ,  C12N15/86 ,  C12Q1/34 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/50 ,  G01N33/576 ,  C07H21/02 ,  C07H21/04 ,  C12N9/00 ,  G01N33/53

CPC分类号： G01N33/502 ,  C07K14/005 ,  C12N15/86 ,  C12N2730/10122 ,  C12N2840/203 ,  C12Q1/34 ,  C12Q1/6897 ,  C12Q1/707 ,  G01N33/5008 ,  G01N33/5067 ,  G01N33/5767 ,  G01N2333/18

摘要： The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity

公开(公告)号：EP1541135A4

公开(公告)日：2005-09-28

申请号：EP03761834

申请日：2003-06-27

申请人： JAPAN SCIENCE & TECH AGENCY

发明人： KURODA SHUNICHI ,  TANIZAWA KATSUYUKI ,  KONDO AKIHIKO ,  UEDA MASAKAZU ,  SENO MASAHARU ,  TADA HIROKO

IPC分类号： C12N15/09 ,  A61K9/51 ,  A61K38/00 ,  A61K47/42 ,  A61K48/00 ,  A61P1/16 ,  A61P35/00 ,  A61P43/00 ,  C07K14/02 ,  C12N1/19 ,  C12N5/10 ,  C12N15/88

CPC分类号： A61K9/5169 ,  A61K38/00 ,  A61K48/00 ,  A61K48/0025 ,  C07K14/005 ,  C12N15/88 ,  C12N2730/10122

摘要： A hollow nanoparticle which comprises a protein (for example, hepatitis B virus surface antigen protein) having a function of recognizing a specific cell such as a liver cell and being capable of forming a particle, wherein a cysteine residue of the protein is replaced by another amino acid. Thus, it is possible to provide a nanoparticle by which a substance can be specifically introduced into a target cell or tissue and which has a stabilized particle structure and enables efficient introduction of the substance, and a drug with the use thereof.

公开(公告)号：EP0993470B1

公开(公告)日：2005-05-11

申请号：EP98937559.7

申请日：1998-06-22

申请人： bioMerieux B.V.

发明人： PAULIJ, Wilhelmina, Petronella ,  VAN KESSEL-KOENS, Marjolijn, Jacqueline

IPC分类号： C07K16/08 ,  C12N5/20 ,  C07K14/02 ,  G01N33/569 ,  G01N33/577

CPC分类号： C07K14/005 ,  C07K16/082 ,  C07K2317/34 ,  C12N2730/10122 ,  Y10S436/82

摘要： The present invention relates to antibodies and other binding molecules specific for hepatitis B viral antigens (HBV), peptides comprising epitopes recognised by such molecules, and cell lines capable of producing antibodies. The invention is further concerned with the use of such molecules in diagnosis of hepatitis B virus (HBV). The invention further relates to a method for the diagnosis of hepatitis B, the method comprising contacting the sample suspected to contain hepatitis B particles or antigens with the specific binding molecule according to the invention. More preferred, the invention relates to a method for the diagnosis of hepatitis B, the method comprising contacting the sample suspected to contain hepatitis B particles or antigens with at least one specific binding molecule directed to the S-region of HBV and at least one specific binding molecule according to the present invention. The invention further relates to an assay kit for the detection of a hepatitis B particle or antigen, the kit comprising a specific binding molecule according to the invention and means for detecting whether the specific binding molecule is bound to a hepatitis B particle or antigen.

公开(公告)号：EP1297109A4

公开(公告)日：2004-12-29

申请号：EP01937883

申请日：2001-06-08

申请人： MELBOURNE HEALTH ,  AUSTIN AND REPATRIATION MEDICA ,  CENT SYDNEY AREA HEALTH SERV

发明人： BARTHOLOMEUSZ ANGELINE INGRID ,  LOCARNINI STEPHEN ALISTER ,  AYRES ANNA ,  LITTLEJOHN MARGARET ROSE ,  MCCAUGHAN GEOFFREY WILLIAM ,  ANGUS PETER WILLIAM

IPC分类号： A61K39/29 ,  C07K14/02 ,  C12N7/00 ,  C12N9/12 ,  C12N15/51 ,  C12N15/54 ,  C12Q1/68 ,  C12Q1/70

CPC分类号： C07K14/005 ,  A61K2039/525 ,  C12N9/1252 ,  C12N2730/10122 ,  C12Q1/706 ,  C12Q2600/156

公开(公告)号：EP0789563B8

公开(公告)日：2004-11-17

申请号：EP95938824.0

申请日：1995-10-05

申请人： APOLLON, INC. ,  The General Hospital Corporation doing business as The Massachusetts General Hospital

发明人： PACHUK, Catherine J. ,  WANDS, Jack ,  WAKITA, Takaji ,  ZURAWSKI, Vincent R., Jr. ,  CONEY, Leslie R. ,  TOKUSHIGE, Katsutoshi

IPC分类号： A61K31/00 ,  A61K35/00 ,  A61K39/145 ,  C12N7/00 ,  C12N7/01 ,  C07K14/02 ,  C07K14/18 ,  A61P31/14

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/51 ,  C07K2319/00 ,  C12N2730/10122 ,  C12N2770/24222

公开(公告)号：EP1140155A4

公开(公告)日：2004-11-03

申请号：EP99966613

申请日：1999-12-22

申请人： MERCK & CO INC

发明人： ZHAO QINJIAN ,  SITRIN ROBERT ,  ABRAHAM DICKY G ,  GERVAIS DAVID P ,  GIMINEZ JUAN

IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/05 ,  A61K39/08 ,  A61K39/09 ,  A61K39/095 ,  A61K39/10 ,  A61K39/13 ,  A61K39/25 ,  A61K39/29 ,  A61K39/295 ,  A61P31/12 ,  C07K14/02 ,  C12P21/02 ,  A61K45/00 ,  C07K14/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/55505 ,  C12N2730/10122 ,  C12N2730/10134

摘要： The present invention provides an improved rHBsAg that exhibits a higher antigenicity and immunogenicity than that previously known in the art. A method of making the improved rHBsAg is also provided. The improved HBsAg is used to provide vaccines with lower amounts of active ingredient, vaccines with higher immunogenicity and combination vaccines which produce and protective immunization against infection by hepatitis B virus and other infectious agents.

公开(公告)号：EP1375511A2

公开(公告)日：2004-01-02

申请号：EP03010010.1

申请日：1994-02-25

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： Chisari, Francis V.

IPC分类号： C07K14/02 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/292 ,  C12N2710/24143 ,  C12N2730/10122 ,  C12N2730/10134 ,  Y10S930/223

摘要： Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.

摘要翻译： 肽用于限定刺激针对乙型肝炎病毒抗原的HLA限制性细胞毒性T淋巴细胞活性的表位。 肽源自HBV包膜区，特别可用于治疗或预防HBV感染，包括刺激慢性感染个体对HBV抗原应答的免疫应答的方法。

公开(公告)号：EP1294893A2

公开(公告)日：2003-03-26

申请号：EP01943625.2

申请日：2001-06-22

申请人： Celltech Pharmaceuticals Limited

发明人： PAGE, Mark ,  LI, Jing-Li ,  PUMPENS, PaulBiomedical Research and Study Centre ,  BORISOVA, Galina,Biomedical Research& Study Ctr.

IPC分类号： C12N15/51 ,  C07K14/02 ,  A61K39/29 ,  A61P31/20

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K48/00 ,  A61K2039/525 ,  C12N2730/10122 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/484

摘要： A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted, said protein comprising the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg, in which case the HBcAg acts as a carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host, for example against hepatitis B virus.

公开(公告)号：EP1206582A4

公开(公告)日：2002-11-20

申请号：EP00993783

申请日：2000-07-05

申请人： TRIMERIS INC

发明人： JEFFS PETER ,  LACKEY JOHN WILLIAM ,  ERICKSON JOEL BURTON ,  LAWLESS MARY K ,  MERUTKA GENE

IPC分类号： G01N33/50 ,  A61K38/16 ,  A61K45/00 ,  A61P31/18 ,  C07K14/02 ,  C07K14/055 ,  C07K14/11 ,  C07K14/115 ,  C07K14/12 ,  C07K14/125 ,  C07K14/13 ,  C07K14/135 ,  C07K14/155 ,  C07K14/16 ,  G01N33/15 ,  G01N33/566 ,  G01N33/569 ,  G01N33/68 ,  C12Q1/70 ,  A61K38/00 ,  A61K39/21 ,  G01N33/53

CPC分类号： C07K14/005 ,  A61K38/162 ,  C12N2710/16322 ,  C12N2730/10122 ,  C12N2740/15022 ,  C12N2740/16222 ,  C12N2760/16122 ,  C12N2760/18122 ,  C12N2760/18422 ,  C12N2760/18522 ,  C12N2760/18722 ,  G01N33/68 ,  G01N2500/00

摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

摘要翻译： 本发明涉及表现出有效的抗逆转录病毒活性的肽。 本发明的肽包含对应于HIV-1LAI gp41蛋白的氨基酸638至673的DP178（SEQ ID：1）肽，以及DP178的片段，类似物和同系物。 本发明进一步涉及这种肽抑制人类和非人类逆转录病毒，特别是HIV向未感染细胞的传播的用途。